Abstract
I describe a case of tachyphylaxis to pramipexole and its management in a patient with bipolar I disorder.
Keywords: Bipolar, Bipolar depression, Drug holiday, Loss of response, Pramipexole, Tachyphylaxis, Tolerance, caramazepine, lamotrigine, modafinil, quetiapine, Parkinson's disease, valproic acid, depression, antidepressants
Letters in Drug Design & Discovery
Title: Pramipexole Tachyphylaxis and its Management in Bipolar Depression
Volume: 9 Issue: 1
Author(s): Verinder Sharma
Affiliation:
Keywords: Bipolar, Bipolar depression, Drug holiday, Loss of response, Pramipexole, Tachyphylaxis, Tolerance, caramazepine, lamotrigine, modafinil, quetiapine, Parkinson's disease, valproic acid, depression, antidepressants
Abstract: I describe a case of tachyphylaxis to pramipexole and its management in a patient with bipolar I disorder.
Export Options
About this article
Cite this article as:
Sharma Verinder, Pramipexole Tachyphylaxis and its Management in Bipolar Depression, Letters in Drug Design & Discovery 2012; 9 (1) . https://dx.doi.org/10.2174/157018012798193008
DOI https://dx.doi.org/10.2174/157018012798193008 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanostructures for Bypassing Blood Brain Barrier
Current Bioactive Compounds Current Quest in Natural Bioactive Compounds for Alzheimer’s Disease: Multi-Targeted-Designed-Ligand Based Approach with Preclinical and Clinical Based Evidence
Current Drug Targets Conantokins Inhibitors of Ion Flow through the N-Methyl-D-Aspartate Receptor Channels
Current Drug Targets Synthetic Cannabinoid Receptor Agonists and Antagonists: Implication in CNS Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Molecular and Biochemical Features in Alzheimers Disease
Current Pharmaceutical Design Epilepsy, Comorbidities and Treatments
Current Pharmaceutical Design Use of Phenytoin, Phenobarbital Carbamazepine, Levetiracetam Lamotrigine and Valproate in Pregnancy and Breastfeeding: Risk of Major Malformations, Dose-dependency, Monotherapy vs Polytherapy, Pharmacokinetics and Clinical Implications
Current Neuropharmacology Unveiling the Anti-convulsant Potential of Novel Series of 1,2,4-Triazine- 6H-Indolo[2,3-b]quinoline Derivatives: <i>In Silico</i> Molecular Docking, ADMET, DFT, and Molecular Dynamics Exploration
Current Computer-Aided Drug Design Drug Repositioning: A Monetary Stratagem to Discover a New Application of Drugs
Current Drug Discovery Technologies Venoms and Poisonings during the Centuries: A Narrative Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Neuroserpin in Bipolar Disorder
Current Topics in Medicinal Chemistry Biomarker-Guided Strategy for Treatment of Autism Spectrum Disorder (ASD)
CNS & Neurological Disorders - Drug Targets NMDA Receptor Pharmacology: Perspectives from Molecular Biology
Current Drug Targets Voltage Gated ion Channels: Targets for Anticonvulsant Drugs
Current Topics in Medicinal Chemistry The Metabolic Basis for Nervous System Dysfunction in Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease
Current Neurovascular Research Recent Advances in Oral Pulsatile Drug Delivery
Recent Patents on Drug Delivery & Formulation Lipid-based Nano-phytomedicines for Disease Treatment and Theranostic Applications
Current Nanomedicine Autophagy Enhancer Carbamazepine Alleviates Memory Deficits and Cerebral Amyloid-β Pathology in a Mouse Model of Alzheimer's Disease
Current Alzheimer Research Convection-Enhanced Delivery: Neurosurgical Issues
Current Drug Targets Metabolic Drug Interactions Between Antidepressants and Anticancer Drugs: Focus on Selective Serotonin Reuptake Inhibitors and Hypericum Extract
Current Drug Metabolism